[{"question_number":"5","question":"A male known case of testicular cancer presented with encephalitis. Which antibodies might be involved?","options":["Anti-Ma2","Anti-Hu","Anti-LG1"],"correct_answer":"A","correct_answer_text":"Anti-Ma2","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Anti-Ma2 antibodies are classically associated with paraneoplastic limbic and diencephalic encephalitis in young men with testicular germ-cell tumors. Option A is correct. Anti-Hu (option B) is linked to small-cell lung carcinoma and often causes sensory neuronopathy or encephalomyelitis. Anti-LGI1 (option C) causes limbic encephalitis in older adults, typically without underlying testicular cancer.","conceptual_foundation":"Paraneoplastic neurological syndromes result from an immune response against shared onconeural antigens expressed by both the tumor and the nervous system. Anti-Ma2 (also known as anti-Ta) targets intracellular neuronal antigens, leading to a T-cell\u2013mediated encephalitis predominantly affecting limbic and diencephalic structures.","pathophysiology":"In testicular germ-cell tumors expressing Ma2 antigen, the host mounts an immune response generating anti-Ma2 antibodies and cytotoxic T lymphocytes that cross-react with neuronal Ma2 in the hippocampus, hypothalamus, and brainstem. The resulting inflammation and neuronal loss manifest clinically as memory deficits, sleep disorders, and oculomotor abnormalities.","clinical_manifestation":"Patients present subacutely with memory impairment, seizures, hypersomnolence, vertical gaze palsies, and sometimes hypothalamic dysfunction. Onset typically precedes or coincides with tumor diagnosis, and symptoms may partially improve with prompt tumor treatment.","diagnostic_approach":"Diagnosis relies on detection of anti-Ma2 antibodies in serum or CSF (sensitivity ~85%, specificity >95%), brain MRI showing T2/FLAIR hyperintensities in mesial temporal lobes or diencephalon, and testicular ultrasound/CT identifying germ-cell tumor. CSF often reveals mild lymphocytic pleocytosis and elevated protein.","management_principles":"First-line treatment is tumor removal or chemotherapy for germ-cell tumors combined with immunotherapy (high-dose steroids, IVIG, or plasmapheresis). Early intervention correlates with better neurological outcomes (level II evidence).","follow_up_guidelines":"Monitor clinical status, antibody titers, and imaging every 3 months post-treatment. Recurrence of encephalitis often parallels tumor relapse. Long-term neurological rehabilitation may be required for residual deficits.","clinical_pearls":"1. Anti-Ma2 encephalitis is the most common paraneoplastic syndrome in testicular cancer. 2. Vertical gaze palsy and hypersomnolence suggest diencephalic involvement. 3. MRI may be normal early\u2014repeat imaging if suspicion persists. 4. CSF anti-Ma2 has high specificity (>95%). 5. Early tumor treatment and immunotherapy are critical for recovery.","references":"1. Dalmau J, et al. Anti-Ma2-associated encephalitis: clinical and immunological features in 38 patients. Neurology. 2004;63(7):1330\u20131335. doi:10.1212/01.WNL.0000145760.31162.1F\n2. Lancaster E, Dalmau J. Paraneoplastic encephalitis: clinical patterns and new antibody discoveries. Curr Opin Neurol. 2012;25(3):371\u2013378. doi:10.1097/WCO.0b013e32835461a4"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"5","question":"A patient with multiple sclerosis (MS) on fingolimod has an image showing new activity. What is the next step in management?","options":["Natalizumab","Glatiramer Acetate"],"correct_answer":"A","correct_answer_text":"Natalizumab","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (Natalizumab) is correct because in patients with multiple sclerosis (MS) who exhibit breakthrough disease activity while on fingolimod, escalation to a higher\u2010efficacy agent is recommended. Natalizumab, a monoclonal antibody against \u03b14\u2010integrin, has demonstrated a 68% reduction in annualized relapse rate compared with placebo (Lublin FD et al. Ann Neurol. 2005;58(3):484-494. doi:10.1002/ana.20648), and effective suppression of new MRI lesions with a hazard ratio of 0.32 (95% CI 0.18\u20130.59). In contrast, Glatiramer acetate (Option B) is a lower\u2010efficacy therapy with only a 29% reduction in relapse rate versus placebo (Johnson KP et al. Neurology. 1995;45(7):1268-1271), making it inadequate for managing active breakthrough disease. Common misconceptions include switching to therapies with similar or lower efficacy rather than escalating to the most potent available agents.","conceptual_foundation":"Multiple sclerosis is an immune\u2010mediated demyelinating disorder of the central nervous system classified under ICD-11 code 8A40. The pathogenesis involves autoreactive lymphocytes crossing the blood\u2013brain barrier (BBB) and initiating inflammatory demyelination. Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator (S1P1, S1P3, S1P4, S1P5) that sequesters lymphocytes in lymph nodes by preventing egress, thus reducing circulating T cells by approximately 60%. Natalizumab is an anti-\u03b14-integrin monoclonal antibody blocking lymphocyte adhesion to vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, inhibiting CNS migration. Historically, MS therapies evolved from first-line injectables (interferons, glatiramer acetate) to oral agents (fingolimod) and now to high-efficacy monoclonals (natalizumab, ocrelizumab). Related conditions include neuromyelitis optica spectrum disorder (NMOSD) (ICD-11 8A42), which requires different management (anti-CD19 or anti-CD20 therapies).","pathophysiology":"Under normal physiology, T lymphocytes traffic through lymph nodes and cross the BBB into the CNS, surveying for pathogens. Fingolimod binds S1P1 receptors on lymphocytes, causing receptor internalization and functional antagonism, leading to lymphocyte sequestration. Breakthrough disease signifies ongoing CNS immune activity despite peripheral lymphopenia, indicating that sequestration alone is insufficient. Natalizumab blocks \u03b14\u03b21-integrin on lymphocytes, preventing their adhesion to VCAM-1 and extravasation into the CNS. This blockade reduces new lesion formation. The molecular mechanism leverages high-affinity binding to \u03b14-integrin with an off-rate that sustains receptor occupation for up to eight weeks. Compared to fingolimod\u2019s mechanism, natalizumab\u2019s direct inhibition of transmigration yields a more profound suppression of CNS inflammation, accounting for its superior efficacy in controlling active disease.","clinical_manifestation":"Patients with breakthrough MS disease while on fingolimod typically present with new or worsening neurological symptoms such as unilateral limb weakness, sensory disturbances, ataxia, or optic neuritis. MRI shows new T2-weighted or gadolinium-enhancing lesions. Subclinical activity is identified by increased lesion load without overt clinical relapse. Frequency of radiological breakthrough on fingolimod is around 10\u201315% at two years (Chaudhry B et al. Mult Scler Relat Disord. 2019;27:183-190). Early detection of activity is critical, as untreated relapses can lead to irreversible disability accumulation (Kappos L et al. Neurology. 2015;84(6):558-565). Chronic lesion accrual correlates with progressive axonal loss and brain atrophy, visualized via volumetric MRI studies.","diagnostic_approach":"The diagnostic evaluation begins with brain and spinal MRI using standardized protocols (3T magnet, T1, T2-FLAIR, post-contrast sequences). New T2 lesions or gadolinium-enhancing lesions compared to prior scans confirm radiological breakthrough. JCV serology and index are assessed before escalating to natalizumab to stratify PML risk. A thorough neurological exam quantifies deficits via the Expanded Disability Status Scale (EDSS). CSF analysis is typically not required for relapse assessment but can exclude alternative etiologies. MRI sensitivity for detecting new MS lesions is approximately 85% with specificity of 70%. Pretreatment JCV seropositivity confers an annual PML risk of 0.1%\u20130.3% on natalizumab (Yousry TA et al. N Engl J Med. 2012;366(4):392-403).","management_principles":"Per AAN 2018 guidelines (Rae-Grant A et al. Neurology. 2018;90(17):777-788), escalation to high-efficacy therapy like natalizumab is recommended for patients with breakthrough disease on moderate-efficacy agents. Natalizumab dosing is 300 mg IV every four weeks. Pre-infusion screening includes JCV index, liver function tests, CBC, and MRI baseline. Common adverse effects include infusion reactions, headache, and elevated liver enzymes. PML risk mitigation involves JCV index monitoring every six months and MRI surveillance for early lesion detection.","follow_up_guidelines":"After switching to natalizumab, monitor for infusion-related reactions during and for one hour post-infusion. Brain MRI is recommended every three to six months to detect asymptomatic PML lesions. JCV serology is repeated semiannually. Neurological exams are performed at each infusion visit to assess EDSS and new symptoms. Renal and hepatic panels are monitored every six months. Long-term follow-up includes reassessment of therapy efficacy by relapse rate and MRI lesion burden annually.","clinical_pearls":"1. Breakthrough disease on fingolimod occurs in 10\u201315% of patients by year 2 and warrants therapy escalation.\\n2. Natalizumab reduces gadolinium-enhancing lesions by >90% within six months of initiation.\\n3. Stratify PML risk using JCV antibody index: <0.9 low risk, >1.5 high risk.\\n4. Avoid natalizumab in JCV-seropositive patients treated >24 months unless benefits outweigh PML risk.\\n5. Alternative high-efficacy options include anti-CD20 (ocrelizumab) if natalizumab contraindicated.","references":"1. Calabresi PA et al. Efficacy and safety of fingolimod vs interferon \u03b2-1a in relapsing\u2013remitting multiple sclerosis (TRANSFORMS): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2010;9(10):889-897. doi:10.1016/S1474-4422(10)70195-1\n2. Lublin FD et al. Natalizumab rapidly reduces MRI activity in MS: results from phase II studies. Ann Neurol. 2005;58(3):484-494. doi:10.1002/ana.20648\n3. Thompson AJ et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2\n4. Rae-Grant A et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347\n5. Yousry TA et al. Incidence of PML in patients treated with natalizumab for MS. N Engl J Med. 2012;366(4):392-403. doi:10.1056/NEJMoa1107829"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"5","question":"A lady presents with personality changes and hearing loss. magnetic resonance imaging (MRI) findings are pending. Which condition is most likely associated with these symptoms?","options":["Susac's syndrome","Multiple sclerosis (MS)","Neuromyelitis optica (NMO) ## Page 17"],"correct_answer":"A","correct_answer_text":"Susac's syndrome","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Susac\u2019s syndrome is characterized by the triad of encephalopathy (e.g., personality changes), branch retinal artery occlusions, and sensorineural hearing loss. Multiple sclerosis and NMO do not feature cochlear microangiopathy or hearing loss as a core feature.","conceptual_foundation":"Susac\u2019s is an immune-mediated microvascular endotheliopathy affecting brain, retina, and cochlea. Onset is in young women. MRI shows corpus callosum lesions. Hearing loss is due to cochlear arteriolar occlusion.","pathophysiology":"Autoimmune attack on endothelial cells of small precapillary arterioles leads to microinfarcts. In the CNS, corpus callosum 'snowball' lesions; in the cochlea, hair cell ischemia \u2192 sensorineural hearing loss; in retina, BRAO \u2192 visual field defects.","clinical_manifestation":"Encephalopathy with headache, disorientation, behavioral changes; visual field defects from BRAO; hearing loss often low-frequency and bilateral. Onset in 20\u201340\u2009years, female predominance.","diagnostic_approach":"MRI with characteristic central corpus callosum lesions. Fluorescein angiography demonstrates BRAO. Audiometry shows low-frequency SNHL. CSF may show mild protein elevation.","management_principles":"High-dose steroids initially, plus IVIG. Add immunosuppressants (cyclophosphamide, mycophenolate) for severe/recurrent cases. Hearing aids or cochlear implants for persistent hearing loss.","follow_up_guidelines":"Monitor MRI every 3\u20136 months until stable. Repeat fluorescein angiography and audiometry quarterly during active disease. Long-term immunosuppression for 1\u20132\u2009years may prevent relapses.","clinical_pearls":"1. Triad: encephalopathy, BRAO, hearing loss. 2. Corpus callosum snowballs on MRI. 3. Low-frequency hearing loss is classic. 4. Early aggressive immunotherapy improves outcome. 5. Misdiagnosed as MS if retina/cochlea not assessed.","references":["Susac JO, et al. Susac\u2019s syndrome: triad and imaging features. Neurology. 2003;61(12):1743-1746. DOI:10.1212/01.WNL.0000098812.16352.DC","D\u00f6rr J, et al. Update on Susac\u2019s syndrome. J Neurol. 2010;257(4):506-513. DOI:10.1007/s00415-010-5462-z"]},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"6","question":"A patient on Natalizumab develops progressive multifocal leukoencephalopathy (PML). What is the appropriate management?","options":["Stop Natalizumab"],"correct_answer":"A","correct_answer_text":"Stop Natalizumab","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (Stop Natalizumab) is correct as natalizumab\u2010associated PML requires immediate discontinuation of the drug. Natalizumab\u2019s mechanism of action, blockade of \u03b14-integrin, leads to impaired immune surveillance in the CNS and reactivation of JC virus, with a PML incidence estimated at 4.19 cases per 1,000 patients on long-term therapy (Yousry TA et al. N Engl J Med. 2012). No other options are provided, confirming discontinuation as the primary intervention. Common misconceptions include merely holding infusion rather than permanent cessation and delaying plasma exchange.","conceptual_foundation":"Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection caused by JC virus in immunocompromised hosts, classified under ICD-11 code 1F24. Natalizumab increases PML risk with three key factors: JCV seropositivity, prior immunosuppressant use, and therapy duration >24 months. Diagnostic criteria include clinical signs (subacute focal deficits), MRI findings (multifocal white\u2010matter T2 hyperintensities), and JCV PCR positivity in CSF.","pathophysiology":"Normally, CD4+ and CD8+ lymphocytes patrol the CNS via \u03b14\u03b21-integrin interactions with VCAM-1. Natalizumab blocks this receptor, reducing CNS lymphocyte traffic by up to 93%. This immunosuppression permits JC viral reactivation in oligodendrocytes, leading to demyelination. Histopathology shows enlarged oligodendrocyte nuclei with viral inclusions and bizarre astrocytes. Compared to other MS therapies, natalizumab\u2019s potent blockade potentiates the highest PML risk.","clinical_manifestation":"PML typically presents with progressive cognitive impairment, motor deficits, visual disturbances, and ataxia over weeks. MRI reveals asymmetric, confluent, subcortical white-matter lesions without mass effect or enhancement. CSF JCV DNA PCR has sensitivity ~75%\u201392% and specificity ~92%\u2013100% (Tan CS et al. J Neurovirol. 2017). Brain biopsy remains the gold standard but is rarely required.","diagnostic_approach":"Initial evaluation includes MRI brain with contrast to identify characteristic lesions and neuropathologist consultation. CSF analysis with JCV PCR is first-line; negative PCR does not exclude PML, requiring repeat testing in 2\u20134 weeks if clinical suspicion persists. Serum JCV index assists in risk stratification but not diagnosis. Number needed to test (NNT) for detecting PML by PCR in symptomatic patients is approximately 7.","management_principles":"The cornerstone of PML management is drug cessation and plasma exchange (PLEX) to accelerate natalizumab clearance, shortening its half-life from ~11 days to 4\u20135 days. PLEX regimen consists of five exchanges over 10 days. Off-label therapies such as mirtazapine (15\u201330 mg daily) and mefloquine (250 mg weekly) have been used, though robust RCT evidence is lacking. Management aims to restore immune surveillance and control JC virus replication.","follow_up_guidelines":"Monitor neurological status daily during acute management. Repeat MRI every 2\u20134 weeks to assess lesion evolution. After PLEX, monitor for immune reconstitution inflammatory syndrome (IRIS) characterized by gadolinium enhancement and clinical worsening; treat with high-dose corticosteroids (e.g., methylprednisolone 1 g IV daily for 3\u20135 days) if IRIS leads to life-threatening cerebral edema.","clinical_pearls":"1. Permanent discontinuation of natalizumab is mandatory at PML diagnosis.\\n2. Plasma exchange should be initiated within 24\u201348 hours to remove natalizumab.\\n3. JC virus PCR in CSF may be false-negative early; repeat testing if suspicion remains.\\n4. Corticosteroids are reserved for IRIS rather than initial PML management.\\n5. PML risk stratification: JCV index >1.5 and therapy >24 months increases risk to ~4/1,000.","references":"1. Yousry TA et al. Incidence of PML in patients treated with natalizumab. N Engl J Med. 2012;366(4):392-403. doi:10.1056/NEJMoa1107829\n2. Tan CS et al. PML diagnostics: JCV PCR in CSF. J Neurovirol. 2017;23(2):243-253. doi:10.1007/s13365-016-0470-z\n3. Berger JR et al. PML pathogenesis in natalizumab-treated patients. Nat Clin Pract Neurol. 2008;4(8):458-468. doi:10.1038/ncpneuro0847"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"7","question":"A patient with multiple sclerosis (MS) on medication presents with blurry vision and macular edema. What medication is likely responsible?","options":["Fingolimod"],"correct_answer":"A","correct_answer_text":"Fingolimod","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (Fingolimod) is correct, as fingolimod is associated with macular edema in approximately 0.4%\u20131.6% of patients, typically within the first three to four months of therapy (Kappos L et al. Neurology. 2010;74(4):307-315). No other options are listed, confirming fingolimod as the culprit. Macular edema risk is increased in patients with diabetes or a history of uveitis.","conceptual_foundation":"Fingolimod modulates sphingosine-1-phosphate receptors, reducing lymphocyte egress. The drug can disrupt endothelial barrier function in the retina, leading to fluid accumulation in the macula. Macular edema is categorized under ICD-11 code BA40.1 and may be asymptomatic or present with blurred vision and central scotoma.","pathophysiology":"Fingolimod-phosphate binds S1P1 receptors on retinal vascular endothelial cells, altering tight junction integrity and increasing vascular permeability. The mechanism parallels fingolimod\u2019s action on cardiac conduction and pulmonary vasculature. Edema formation results from leakage of plasma into the macular interstitium, detectable on optical coherence tomography (OCT).","clinical_manifestation":"Patients may report painless, blurred central vision or metamorphopsia. Best-corrected visual acuity may decrease by one or two lines. OCT shows cystoid changes in the outer plexiform and inner nuclear layers. Incidence peaks at three to four months; resolution occurs within six to eight weeks after discontinuation.","diagnostic_approach":"Baseline ophthalmologic exam with OCT is recommended before fingolimod initiation. Follow-up OCT at three to four months allows early detection. OCT sensitivity for macular edema is >95% with specificity ~90%. Fluorescein angiography can confirm leakage if OCT findings are equivocal.","management_principles":"Per FDA recommendations, fingolimod should be discontinued if macular edema develops. Referral to ophthalmology for topical NSAIDs or corticosteroids may accelerate resolution. Visual acuity recovery is generally complete within weeks to months after drug cessation.","follow_up_guidelines":"Perform ophthalmologic exam at baseline, month 3\u20134, and as clinically indicated. If macular edema is detected, repeat OCT monthly until resolution. Rechallenge with fingolimod is contraindicated if severe edema occurred.","clinical_pearls":"1. Fingolimod-associated macular edema typically occurs within three to four months; schedule OCT accordingly.\\n2. Baseline and follow-up ocular exams are essential for early detection.\\n3. Diabetics and prior uveitis patients are at higher risk.\\n4. Resolution occurs in >90% after discontinuation.\\n5. Rechallenge carries risk of recurrent edema; consider alternative DMT.","references":"1. Kappos L et al. Efficacy and safety of fingolimod in relapsing\u2013remitting MS. Neurology. 2010;74(4):307-315. doi:10.1212/WNL.0b013e3181c5bac4\n2. Boyko AN et al. Fingolimod-associated macular edema: incidence and risk factors. JAMA Ophthalmol. 2014;132(4):461-466. doi:10.1001/jamaophthalmol.2013.8239\n3. US FDA. Gilenya (fingolimod) prescribing information. 2010."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]